| Data | Hora | Fonte | Título | Código | Companhia |
| 28/07/2011 | 12:15 | Zacks | AMAG Trims Loss, Sales Remain Weak - Analyst Blog | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 28/07/2011 | 09:55 | Zacks | Celgene Tops, Lifts View - Analyst Blog | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 28/07/2011 | 09:00 | Business Wire | Allos Therapeutics to Report Second Quarter 2011 Results on August 4, 2011 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 27/07/2011 | 13:21 | Edgar (US Regulatory) | Filing of certain prospectuses and communications in connection with business combination transactions (425) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 22/07/2011 | 07:02 | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 21/07/2011 | 19:39 | Business Wire | The Law Firm of Weiss & Lurie Announces Investigation of Allos Therapeutics, Inc. | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 21/07/2011 | 18:25 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (SC 13D/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 21/07/2011 | 17:05 | Business Wire | Law Offices of Howard G. Smith Announces Investigation of Allos Therapeutics, Inc. | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 21/07/2011 | 16:37 | Business Wire | Bull & Lifshitz, LLP Announces Investigation of Allos Therapeutics, Inc. | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 21/07/2011 | 11:01 | Business Wire | Goldfarb Branham Law Firm LLP Investigates Allos Therapeutics Inc Company | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 21/07/2011 | 09:00 | Zacks | AMAG to Merge with Allos - Analyst Blog | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 20/07/2011 | 22:55 | Business Wire | MURRAY FRANK LLP Investigates Allos Therapeutics, Inc. | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 20/07/2011 | 22:40 | Business Wire | The Briscoe Law Firm and Powers Taylor, LLP Announce Investigation of Allos Therapeutics, Inc. | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 20/07/2011 | 21:21 | Business Wire | Robbins Umeda LLP Announces an Investigation of Allos Therapeutics, Inc. | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 20/07/2011 | 17:05 | Business Wire | Law Office of Brodsky & Smith, LLC Announces Investigation of Allos Therapeutics, Inc. | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 20/07/2011 | 13:39 | Business Wire | The Law Firm of Levi & Korsinsky, LLP Announces Investigation of Allos Therapeutics, Inc. | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 20/07/2011 | 13:16 | Business Wire | Harwood Feffer LLP Announces Investigation of Allos Therapeutics, Inc. | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 20/07/2011 | 11:37 | Business Wire | Faruqi & Faruqi, LLP Announces Investigation of Allos Therapeutics, Inc. | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 20/07/2011 | 11:37 | Business Wire | Kendall Law Group Investigates Allos Therapeutics, Inc. | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 20/07/2011 | 08:00 | Business Wire | AMAG Pharmaceuticals and Allos Therapeutics Agree to Merge to Strengthen Commercial Portfolio and Achieve Cost Synergies | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 13/07/2011 | 17:21 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 20/06/2011 | 10:30 | Zacks | Label Expansion for CELG's Istodax - Analyst Blog | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 17/06/2011 | 18:29 | Business Wire | Data Shows Activity of FOLOTYN® in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Following Treatment with ... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 17/06/2011 | 10:00 | Marketwired | Research Report on Allos Therapeutics, Inc. and Spectrum Pharmaceuticals, Inc. -- BioPharm Looks Forward for Growth | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 17/06/2011 | 07:50 | GlobeNewswire Inc. | Allos Therapeutics is MicroStockProfit.com's Biopharm Feature Stock | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 17/06/2011 | 03:30 | Business Wire | Data Suggests Treatment with FOLOTYN® Reverses Trend of Progressive Resistance Observed in Patients with Drug-Resistant Rela... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 16/06/2011 | 03:30 | Business Wire | COMPLETE Registry Provides First Glance into Treatment Patterns for Patients with Peripheral T-Cell Lymphoma | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 08/06/2011 | 10:00 | Business Wire | FOLOTYN® Data to be Presented at the Congress of the European Hematology Association & the International Conference on Malig... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/06/2011 | 16:57 | Edgar (US Regulatory) | Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 20/05/2011 | 13:49 | Zacks | Risk-Reward Balanced at Allos - Analyst Blog | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |